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Abstract
Background: Sex-specific differences regarding the transmissibility and the course of infection are the rule rather than the
exception in the epidemiology of sexually transmitted infections (STIs). Human papillomavirus (HPV) provides an example:
disease outcomes differ between men and women, as does the potential for transmission to the opposite sex. HPV
vaccination of preadolescent girls was recently introduced in many countries, and inclusion of boys in the vaccination
programs is being discussed. Here, we address the question of whether vaccinating females only, males only, or both sexes
is the most effective strategy to reduce the population prevalence of an STI like HPV.
Methods and Findings: We use a range of two-sex transmission models with varying detail to identify general criteria for
allocating a prophylactic vaccine between both sexes. The most effective reduction in the population prevalence of
infection is always achieved by single-sex vaccination; vaccinating the sex with the highest prevaccine prevalence is the
preferred strategy in most circumstances. Exceptions arise only when the higher prevaccine prevalence is due to a
substantially lower rate of natural immunity, or when natural immunity is lifelong, and a prolonged duration of
infectiousness coincides with increased transmissibility. Predictions from simple models were confirmed in simulations
based on an elaborate HPV transmission model. Our analysis suggests that relatively inefficient genital transmission from
males to females might render male vaccination more effective in reducing overall infection levels. However, most existing
HPV vaccination programs have achieved sufficient coverage to continue with female-only vaccination.
Conclusions: Increasing vaccine uptake among preadolescent girls is more effective in reducing HPV infection than
including boys in existing vaccination programs. As a rule, directing prophylactic immunization at the sex with the highest
prevaccine prevalence results in the largest reduction of the population prevalence.
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Introduction
Key issues in the allocation of limited public health resources for
the control of sexually transmitted infections (STIs) are (a) whether
interventions are as effective for males as for females; and (b)
whether directing interventions at both males and females adds to
the population-level impact of directing interventions at one sex
alone. These topics have been addressed in relation to gonorrhea
and chlamydia prevention strategies [1–3], and with respect to sex-
specific interventions against HIV [4–6]. They are also especially
relevant for the question of whether or not to include males in
human papillomavirus (HPV) vaccination programs. Vaccine-
preventable HPV imposes a significant burden on global health; it
has been associated with over 70% of cervical cancers [7], over
80% of anal cancers [8], and a smaller yet substantial proportion
of penile, vulvar, vaginal, and head and neck cancers [8–10]. HPV
vaccination programs are currently directed at females only,
because HPV-related morbidity and mortality are higher among
women than among men. The rationale for male inclusion would
be twofold: men benefit directly from immunization against HPV-
related diseases, and vaccination of boys could help to further
decrease the circulation of HPV in the population and indirectly
improve the protection of women.
In many countries, vaccination against infection with the two
most common oncogenic papillomavirus types, HPV16 and
HPV18, was recently introduced or will be introduced soon.
Among women without previous exposure to these types,
vaccination against HPV16 and HPV18 has shown high, sustained
efficacy against persistent type-specific infections and precancerous
lesions of the cervix, vulva, and vagina [11,12]. Recent data also
suggest high efficacy against vaccine-type infections and external
genital lesions in men [13]. In addition, the vaccine Gardasil
(Merck) also prevents infection with HPV6 and HPV11, types that
are associated with anogenital warts [11,14], most commonly
found in men [15]. Gardasil has been licensed for use in males up
to 26 y of age, both by the United States Food and Drug
Administration and the European Medicines Agency. The vaccine
Cervarix (GlaxoSmithKline) targets only HPV types 16 and 18
and has not (yet) been licensed for use in males.
The primary target for HPV vaccination currently is girls in age
groups when HPV16/18 infection is not yet common, i.e., before
or just after initiation of sexual activity. In the US, the Advisory
Committee on Immunization Practices has recommended HPV
vaccination for routine use in preadolescent girls and young
women since 2006, and is currently considering inclusion of males
into the vaccination program [16]. Despite limited data, HPV
vaccination for boys is already licensed in several countries, and it
is expected that other countries will consider licensure once more
data become available. But the question of whether or not HPV
vaccination should be recommended for boys depends only in part
on vaccine efficacy, since a program directed at girls already
confers health benefits for boys via a reduced transmission of HPV
[14]. In Australia, where coverage rates for ongoing vaccination of
12- to 13-y-old girls approach 80%, a modeling study estimated
that the current female-only vaccination program will achieve
73% of the maximum possible vaccine-conferred benefit to males
[17].
Two recent studies have calculated the cost-effectiveness of
extending HPV programs in the US to include boys [18,19]. The
outcomes appear very sensitive to the precise modeling assump-
tions used, but a common finding is that the cost-effectiveness of
male vaccination depends crucially on female vaccine coverage—
male vaccination being a more attractive option when immuni-
zation rates of girls are low. This finding is in line with other
modeling studies, estimating few additional benefits from male
vaccination at 70% to 80% coverage of girls, particularly if vaccine
efficacy is high and the duration of vaccine protection is lifelong
[20,21]. A basic question that has not been addressed so far is
whether infection levels are more effectively reduced by stimulat-
ing vaccine uptake in girls when female coverage is low, or by
extending coverage to males. This question is highly relevant in
view of the relatively low coverage achieved so far in numerous
countries that have introduced HPV vaccination. In the US, only
44% of female adolescents 13 to 17 y of age had received $1 dose
of HPV vaccine as of 2009 [22]. Only 27% had received three
doses, required for optimal vaccine protection against incident and
persistent HPV16/18 infection [23]. In the Netherlands, the
difference between coverage of $1 dose and three doses is small,
the latter figure being 53% as of 2010 [24].
Here, we address the question of whether increasing protection
of females only, of males only, or of both males and females, is the
most effective strategy for reducing the prevalence of an STI in a
heterosexual population. In addressing this question, we allow for
differences between the sexes in the transmissibility, the course of
infection, the degree of natural immunity, or any combination
thereof. We do not consider sex-related differences in disease-
associated mortality. Throughout we restrict ourselves to prophy-
lactic interventions that are applied before girls or boys become
sexually active, which precludes the targeting of highly sexually
active individuals.
Methods
We use mathematical models of infection and transmission in
heterosexual populations. These transmission models allow us to
investigate how prophylactic vaccine is best distributed between
males and females in order to lower the population prevalence of
infection. The central idea is that immunization benefits not only
the individual but also the population at large, because vaccination
confers indirect protection to nonvaccinated individuals by
lowering transmission of vaccine-preventable disease (herd immu-
nity). This is especially important for STIs, as immunization of
individuals of a single sex offers indirect protection against
infection to members of the opposite sex. In principle, vaccinating
a substantial proportion of one sex may suffice to eliminate
infection from the entire heterosexual population [25].
To derive general rules for allocating prophylactic vaccine
between two sexes, we first use a standard model of heterosexual
transmission. The standard transmission model partitions the
population into fractions that are susceptible (S), infectious (I), and
resistant (R) to infection, resistance being due to natural immunity
or to vaccination. In the heterosexual transmission model, each
compartment is split in two sexes (males and females, indexed by
the suffix k). Taken together, the change in the proportion of
susceptible, infectious, and resistant individuals of either sex is
described by the following set of ordinary differential equations:
_Sk~d(1{vk){lkSkz(1{fk)akIk{dSk
_Ik~lkSk{akIk{dIk
_Rk~d vkzfkakIk{dRk
ð1Þ
We do not incorporate infection-induced mortality, and we
assume that the heterosexual population is in demographic
equilibrium. By taking equal birth and death rates d in males
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and females, each sex constitutes half of the heterosexual
population. The parameter vk denotes the effective vaccine
coverage among individuals of sex k, i.e., the fraction vaccinated
times the probability that the vaccinee is protected against
infection by vaccine types. The parameter lk denotes the sex-
specific force of infection, which is the product of the rate c at
which sexual contacts are made, the probability bk that infection is
transmitted from the opposite sex k9, and the probability that a
sexual partner is infectious:
lk~
cbk0Ik0
Sk0zIk0zRk0
ð2Þ
In this standard model, sexual activity is assumed equal between the
sexes. Of importance, males and females may differ in the
transmission probability bk as well as in the rate ak at which they
recover from being infectious. Throughout, we assume that the
duration of infectiousness corresponds to the duration of infection.
The parameter fk denotes the sex-specific fraction of individuals who
become immune following infection; such immunity is assumed to
be lifelong. Note that the model is generic in the sense that
individuals may intermittently go through susceptible and infectious
stages (with ff = fm = 0), as in susceptible-infected-susceptible (SIS)
models, or go through the susceptible, infectious, and immune
stages only once (with ff = fm = 1), as in susceptible-infected-resistant
(SIR) models. The susceptible-infected model, without recovery
from infection (af =am = 0), is also a special case of this model.
To test the rules for sex-specific vaccine allocation in more
detail, we employed computer simulation of a HPV transmission
model that has been introduced in earlier studies [26,27]. Briefly,
this model stratifies the population not only by sex but also by age
and level of sexual activity. It gives a detailed description of the
sexual contact network in the Netherlands, and thus explicitly
acknowledges the considerable heterogeneity in the risk of HPV
infection. Heterogeneous sexual activity is known to impede the
elimination of STIs from an at-risk population [28,29]. Hence, this
model is more realistic than the standard transmission model. In
addition, it contains a description of the various stages through
which women may progress to cervical cancer and incorporates
the effect of population-based screening for precancerous lesions.
It is assumed that women remain infectious until naturally
occurring viral clearance or treatment for cancer or precancerous
lesions. Only a single infection stage for men is considered, as it is
assumed that male HPV infection is generally cleared within 1 y
[30].
The HPV transmission model describes the dynamics of one
particular strain of HPV, under the assumption that the
transmission dynamics of types of oncogenic HPV are indepen-
dent of one another. The model has been parameterized to match
prevaccine data on type-specific HPV infection and cervical
disease in the Netherlands [31–33]. Results of female-only, male-
only, and two-sex vaccination are illustrated for HPV16, assuming
100% vaccine efficacy among those naı¨ve to HPV16. This is close
to the value observed in clinical trials regarding HPV16-positive
precancerous lesions in the per-protocol treatment arm [11,12].
Analyses of types other than HPV16 yield qualitatively similar
outcomes, although the overall impact of vaccination diminishes
with smaller type-specific efficacy.
Results
Sex-Specific Immunization to Eliminate Infection
Sustained transmission of an infectious disease in heterosexual
populations requires that the basic reproduction number R0
(defined as the number of secondary infections caused by one
typical infectious individual if all contacts are with susceptible
individuals) is greater than one over two generations of
transmission—from men to women and back to men [34]. The
projected reproduction number in a partly vaccinated population,
Rv, is related to the basic reproduction number R0 without
vaccination as follows [35]:
Rv~R0
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(1{vf )(1{vm)
p
ð3Þ
Here, vf denotes the immunization coverage among females, and
vm denotes the immunization coverage among males. This
equation implies that it makes no difference whether the fraction
of susceptible males or females is diminished in order to reduce the
basic reproduction number. Indeed, the critical immunization
coverage vc needed to achieve Rv,1 is the same whether only
males or only females are vaccinated:
vc~1{
1
R0,fR0,m
ð4Þ
Here, R0,f is the basic reproduction number for heterosexual
transmission from women to men and R0,m is the basic
reproduction number for heterosexual transmission from men to
women. Note that reducing either sex-specific reproduction
number below one may neither be necessary nor sufficient to
achieve Rv,1. Also note that low or waning vaccine efficacy may
cause even complete coverage of a single sex to be insufficient for
elimination. We refer to others for an analysis of conditions in
which vaccination of both sexes may be needed to achieve Rv,1
[35,36].
There is no combined allocation scheme for a fixed amount of
vaccine that reduces the reproduction number Rv more effectively
than male-only or female-only vaccination (Figure 1A). Thus, if
the objective of control is to eliminate infection from the
heterosexual population with as few vaccine doses as possible, it
is best to vaccinate either girls or boys but not both. Moreover, the
choice between vaccinating males or females is arbitrary if vaccine
efficacy is the same between the sexes. Sex-specific differences in
key epidemiological parameters have no bearing on the effective-
ness of viral elimination by vaccinating either sex. Yet, as long as
coverage remains below the level required for elimination, it does
matter which sex is being vaccinated in light of sex-specific
differences in the prevalence of infection.
Sex-Specific Immunization to Reduce the Population
Prevalence of Infection
If the fraction of individuals developing natural immunity is the
same among males and females (i.e., ff = fm), the steady-state
prevalence of infection prior to the introduction of vaccine is
highest in sex k either if transmissibility is lower in this sex given
equal recovery rate a, or if recovery is slower in this sex given
equal transmission probability b (Text S1). The prevaccine
prevalence will thus be highest among women in case of a higher
male-to-female transmission probability than vice versa, or a
slower recovery of infection in women as compared to men. The
difference in prevalence between the sexes can be leveled by
vaccination only if vaccine is predominantly directed at the sex
with the highest prevaccine prevalence of infection. Such a
strategy makes sense from the perspective of prevalence reduction.
Indeed, if the objective of vaccination is to achieve the largest
reduction in population prevalence, one should start by vaccinat-
ing the sex with the highest prevalence of infection (Text S2).
Sex-Specific Immunization for STIs
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Following this line of reasoning, expanding the vaccination
program to include both sexes could be considered reasonable
once the difference in prevalence between the sexes is leveled.
Note that this can be achieved at a level of immunization much
smaller than the critical coverage needed for viral elimination
(Text S1). Yet up to the point of elimination, increasing the
immunization coverage of the sex with the highest prevaccine
prevalence remains the most effective strategy for lowering
infection levels in the heterosexual population (Text S2). The
same principle applies if one adopts a global minimization
criterion, applicable to the situation wherein an allocation scheme
for a given total amount of vaccine v,vc is desired (Text S3).
Results are unaltered if a lower recovery rate coincides with a
lower transmissibility to the opposite sex, e.g., female-only
vaccination is the preferred strategy if af,am together with
bf,bm (Figure 1B).
Vaccinating the sex with the highest prevaccine prevalence of
infection may not achieve the largest reduction in population
prevalence if there is a trade-off along the lines ak.ak9 together
with bk,bk9, i.e., when a faster recovery of infection coincides with
a lower transmissibility to the opposite sex. As algebraic analyses
become intractable in such an instance, we resorted to simulation
by drawing random values for sex-specific recovery rates and
transmission probabilities from a uniform distribution between 0
and 1. We retained n = 10,000 combinations that yielded a basic
reproduction number larger than one (conditional on a contact
rate of one partner per year and a death rate of 0.02 deaths per
year). The remaining set of parameters was split into equal-sized
subsets on the condition that the highest recovery rate and
transmission probability occurred in the same sex or not. Next, we
determined which allocation scheme minimizes the total preva-
lence of infection at a certain vaccine coverage v, taken either close
to the prevaccine situation or close to the critical immunization
coverage.
Interestingly, vaccinating the sex with the highest prevaccine
prevalence always yielded the largest reduction in heterosexual
infection levels in a SIS system (Table 1), but not necessarily in a
SIR system (Table 2). Whenever vaccination of the high-
prevalence sex was not the most effective strategy, reduced
recovery of infection was the cause of the higher prevaccine
prevalence. Conversely, if the higher prevaccine prevalence was
due to a reduced transmissibility to the opposite sex, vaccinating
the sex with higher prevalence was always the most effective
strategy. An intuitive explanation for this finding is that, in a SIR
system, vaccinating those who experience the highest force of
infection is more effective than vaccinating those who experience
the longest duration of infectiousness. In a SIS system, vaccinating
individuals with longer infectious periods becomes more important
because individuals may become reinfected and go through
multiple infectious periods. Another interesting finding is that
allocation rules defined on the basis of sex-specific reproduction
numbers invariably performed poorly in minimizing the popula-
tion prevalence of infection.
We evaluated the impact of a small proportion of men who have
sex with men (MSM) in the general population on the
performance of the rule of vaccinating the sex with higher
prevaccine prevalence (Text S4). Performance of this rule was
somewhat reduced by the inclusion of MSM into a SIS system, but
not in a SIR system. Performance was further reduced by an
increasing proportion of bisexual men among MSM, both in SIS
and in SIR systems. However, with 5% of the population being
MSM, of whom 80% were bisexual, the strategy of vaccinating the
high-prevalence sex still achieved minimum possible population
prevalence in over 90% of SIS systems, and over 80% of SIR
Figure 1. The differential impact of sex-specific immunization on the reproduction number and on the prevalence of a
heterosexually transmitted infection. (A) The effect of immunization coverage among females (vf) and males (vm) on the projected reproduction
number in a partly vaccinated population Rv. (B) The effect on the equilibrium prevalence of infection among men, Im, and women, If. Darker colors
correspond to lower values; the region where Rv,1 corresponds to Im+If = 0, i.e., elimination of infection from the heterosexual population. In this
example, R0 = 3.45 and women have both a slower recovery from infection and a lower probability of transmitting infection than men. The largest
reduction in the reproduction number is achieved by allocating all vaccine to a single sex; the choice between vaccinating males or females is
arbitrary. The largest reduction in the equilibrium prevalence of infection is achieved by allocating all vaccine to females, for any given coverage
below the threshold required for elimination.
doi:10.1371/journal.pmed.1001147.g001
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systems. Largest reductions in prevalence among MSM were
observed with male-only vaccination.
At the start of this section, we made the assumption that a similar
fraction of males and females become immune following infection
(i.e., ff = fm). It appears that the strategy of vaccinating the high-
prevalence sex always remains the most effective strategy, whenever
the probability of developing natural immunity in this sex is larger
than in the other sex (Text S2). If the high-prevalence sex has a
smaller probability of developing natural immunity, vaccinating this
sex might not be the most effective strategy. In that case, the higher
prevaccine prevalence is not caused by differences in transmissibility
or recovery of infection, but by a lower degree of natural immunity.
When Should Existing Allocation Schemes Be
Reconsidered?
Suppose a single-sex vaccination program is in place, but this
program does not achieve the maximum possible reduction in the
population prevalence of infection. Would it be more effective to
increase the coverage in the existing single-sex program, or to
switch to universal vaccination? The outcome likely depends on
the immunization coverage that has already been achieved. Close
to the critical immunization coverage vc (on the verge of viral
elimination), one should continue the existing single-sex program.
But at very low immunization coverage (close to the prevaccine
situation), one should switch to a vaccination program directed
only at the other sex. Between these extremes lies some threshold
value below which switching to a two-sex vaccination strategy
might be considered. Numerical analyses demonstrate that this
value is well below 50% immunization coverage for almost all
possible parameter combinations (Figure 2). Note that a two-sex
vaccination strategy can only be considered a marginally attractive
option, because elimination is achieved with fewer vaccine doses if
immunization remains directed at a single sex. Taken together,
most existing HPV vaccination programs appear to have achieved
sufficient coverage to continue with female-only vaccination, even
if vaccinating males from the onset would have brought about a
stronger reduction in the population prevalence of infection.
Application of Allocation Rules to a Detailed HPV
Transmission Model
So far, HPV vaccination has been primarily aimed at
preadolescent girls because, in later life, they carry the highest
risk of complications from infection. Computer simulation suggests
that female vaccination also is the most effective strategy to reduce
HPV prevalence in the heterosexual population (Figure 3A). The
predicted impact of vaccination depends on the heterogeneity in
sexual activity in the at-risk population. A more heterogeneous
sexual contact network leads to a lower degree of herd immunity
and, consequently, to a lower impact of vaccination at a given
coverage (Figure 3B). In view of this heterogeneity and the
generally high transmissibility of vaccine-preventable types of
HPV, viral elimination does not appear to be a reasonable goal of
vaccination. Instead, one should aim for a maximum reduction in
the population prevalence of HPV infection.
Table 1. Success rate of two allocation strategies in minimizing the total population prevalence in a two-sex transmission model
without natural immunity.
Conditions Population to Which Vaccination Is Directed
Sex-Specific Parameters Vaccine Coverage
Sex with Highest Prevalence of
Infection
Sex with Highest Reproduction
Number
a, b highest in the same sex v= 0.05vc 100% 58.1%
v= 0.95vc 100% 58.1%
a, b highest in different sexes v= 0.05vc 100% 58.6%
v= 0.95vc 100% 58.6%
The success rate of an allocation strategy is calculated as the percentage of random parameter combinations for which this strategy achieves the largest reduction in
the total population prevalence of infection. n= 10,000 random combinations of sex-specific recovery rates a and transmission probabilities b were drawn from uniform
distributions between 0 and 1, conditional on R0.1 with contact rate c= 1 and death rate d=0.02 deaths per year. Allocation strategies were evaluated at 5% and 95%
of the critical immunization coverage vc required for elimination of infection from the heterosexual population.
doi:10.1371/journal.pmed.1001147.t001
Table 2. Success rate of two allocation strategies in minimizing the total population prevalence in a two-sex transmission model
with lifelong natural immunity.
Conditions Population to Which Vaccination Is Directed
Sex-Specific Parameters Vaccine Coverage
Sex with Highest Prevalence of
Infection
Sex with Highest Reproduction
Number
a, b highest in the same sex v= 0.05vc 100% 58.5%
v= 0.95vc 100% 58.5%
a, b highest in different sexes v= 0.05vc 72.6% 45.9%
v= 0.95vc 38.9% 12.1%
The success rate of an allocation strategy is calculated as the percentage of random parameter combinations for which this strategy achieves the largest reduction in
the total population prevalence of infection. n= 10,000 random combinations of sex-specific recovery rates a and transmission probabilities b were drawn from uniform
distributions between 0 and 1, conditional on R0.1 with contact rate c= 1 and death rate d=0.02 deaths per year. Allocation strategies were evaluated at 5% and 95%
of the critical immunization coverage vc required for elimination of infection from the heterosexual population.
doi:10.1371/journal.pmed.1001147.t002
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The higher impact of vaccinating girls relative to boys in this
detailed model can be understood in terms of different recovery
rates between the sexes. The model effectively assumes a
prolonged duration of infectiousness in females as compared to
males, because women more often develop a persistent infection.
In addition, we made the simplifying assumptions that males and
females have a similar degree of natural immunity, and that the
probability of male-to-female transmission is the same as that of
female-to-male transmission. Based on the previously derived
allocation rules, female vaccination could already be expected to
yield the largest reduction in population prevalence. Reasoning
further, it can be predicted that male vaccination can only become
Figure 2. The immunization coverage in a girls-only vaccination program below which vaccination of boys is more effective in
reducing prevalence. (A) The threshold coverage for combinations of recovery rate af and am given equal transmission probabilities b=0.9. (B) The
threshold coverage for combinations of transmission probability bf and bm given equal rates of recovery a=0.1. Contact rate c= 1 and death rate
d=0.02 deaths per year. The set of parameters for which male vaccination is an attractive option becomes increasingly restricted with higher female
immunization coverage. Vaccinating males is rarely attractive if at least 40% coverage has been achieved among females.
doi:10.1371/journal.pmed.1001147.g002
Figure 3. The effectiveness of HPV vaccination depends on which sex is being vaccinated and on the heterogeneity in sexual
behavior. (A) The equilibrium prevalence of HPV16 infection in relation to immunization coverage by vaccinating girls only, boys only, or both girls
and boys at an equal rate. (B) The equilibrium prevalence of HPV16 infection in relation to female immunization coverage for various assumptions of
heterogeneity in sexual behavior. Results in (A) assume three dynamic activity classes plus an age-specific partner preference function. The default
parameters were obtained by fitting this model to prevaccine data on HPV16 infection in the Netherlands [26].
doi:10.1371/journal.pmed.1001147.g003
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the more effective strategy under conditions where male-to-female
transmissibility is lower than female-to-male transmissibility, or
where females have a smaller degree of natural immunity than
males.
Incorporating decreased male-to-female transmissibility in our
HPV transmission model (while maintaining a constant R0 by
simultaneously increasing female-to-male transmissibility) lowers
the total prevaccine prevalence of infection and changes the
relative effectiveness of vaccinating girls or boys (Figure 4A). At a
0.6-fold lower probability of transmission in a partnership where
the man rather than the woman is infectious, vaccinating boys
becomes as effective as vaccinating girls in reducing the population
prevalence of HPV infection. A further reduction of male-to-
female transmissibility decreases the threshold for elimination
because of a lowered R0 and causes vaccination of boys to become
more effective than vaccination of girls.
Modeling a relatively smaller degree of natural immunity in
females (which is achieved by increasing the loss of infection-
induced immunity by a factor ten among women in the HPV
transmission model) raises the total prevaccine prevalence of
infection and causes vaccination of boys to become the most
effective strategy (Figure 4B). If the rate at which infection-induced
immunity is lost among men increases, the total prevaccine
prevalence is raised even further, but vaccination of girls remains
the most effective strategy. Again, the allocation rules derived from
the standard model of heterosexual transmission are confirmed in
this detailed HPV transmission model.
Discussion
By exploring various two-sex transmission models, we demon-
strate that directing prophylactic intervention at a single sex more
effectively reduces heterosexual STI transmission than any
allocation that includes both sexes. In addition, we demonstrate
that a strategy of protecting the sex with the highest endemic
prevalence generally achieves the largest reduction in the
population prevalence. The implication of our finding is that the
prevaccine prevalence of infection might be a good proxy to
determine which individuals should be vaccinated in order to
achieve the highest impact of vaccination at the population level.
Our results provide a justification, under most circumstances,
for the intuitively plausible strategy of targeting intervention at the
subgroups that harbor most infections and that act as a reservoir
for transmission. An alternative strategy that uses allocation rules
defined on the basis of sex-specific reproduction numbers would
also be intuitively plausible but performs poorly in minimizing the
population prevalence of infection. Our results can be viewed as a
generalization of a recently formulated argument for prioritization
of vaccination to groups with the highest product of incidence and
force of infection [37]. Although we have already identified several
exceptions (e.g., arising from different degrees of natural immunity
throughout the population), it would be logical and prudent to
further test the generality of the rule of targeting intervention at
the subgroups with the highest endemic prevalence.
The allocation that achieves the largest reduction in the
population prevalence of infection for a fixed amount of vaccine
is not necessarily the most attractive from an economic point of
view. The cost per vaccine dose delivered is subject to logistics, and
universal vaccination could sometimes be a cost-effective alterna-
tive to single-sex vaccination. For example, the variable costs of
vaccine purchase and delivery could be low compared to the total
costs of running a vaccination program. In addition, the marginal
cost of increasing vaccine uptake might depend on the coverage
already achieved and might be different between the sexes. Males
and females, or in the case of preadolescent vaccination, their
parents, likely have different perceptions of the risk from HPV
infection and different attitudes towards vaccination, although
more research is needed to reliably measure vaccine acceptability
Figure 4. The effectiveness of male-only or female-only HPV vaccination depends on sex-specific differences in viral
transmissibility and natural immunity. (A) The equilibrium prevalence of HPV16 infection in relation to immunization coverage for different
assumptions regarding viral transmissibility. (B) The equilibrium prevalence of HPV16 infection in relation to immunization coverage for different
assumptions regarding natural immunity. Solid lines represent a strategy of vaccinating preadolescent girls, and dotted lines represent a strategy of
vaccinating preadolescent boys. Natural immunity is lost over time at a rate k (per year). Default parameters, b=0.8 and k=0.04 for both sexes, were
obtained by fitting this model to prevaccine data on HPV16 infection in the Netherlands [26].
doi:10.1371/journal.pmed.1001147.g004
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[38]. Finally, differences in cost-effectiveness between sex-specific
vaccination programs are determined by the relative benefits of
preventing infections in men and women. For example, HPV
prevention programs started off offering vaccine to females
because it is on average more beneficial to prevent HPV infection
in a woman than in a man. Directing interventions at the sex most
affected by disease makes sense from an equity perspective, and
will also have the strongest impact on heterosexual transmission if
infection is more prevalent in this sex.
Our analysis adds new arguments to the ongoing debate about
whether males should also be offered HPV vaccination [39]. A
common rationale for including boys in existing vaccination
programs is that they experience not only a direct benefit, but that
vaccinating males also creates herd immunity that helps to protect
women [40]. The herd immunity argument can as well be used
against male vaccination, for men already derive a substantial
benefit from female-only vaccination [14,17]. A recent modeling
study concluded that heterosexual males would benefit almost to
the same extent as females from a girls-only HPV vaccination
program, due to herd immunity [21]. We show that, once routine
vaccination of one sex is in place, increasing the coverage in that
sex is much more effective in bolstering herd immunity than
switching to a policy that includes both sexes. Universal
vaccination against HPV should therefore only become an option
when vaccine uptake among girls cannot be further increased.
Adding boys to current vaccination programs seems premature,
because female coverage rates still leave ample room for
improvement in most countries that have introduced HPV
vaccination [41]. So far, only three countries have achieved a
three-dose coverage of 70% or more in females [14,22,24,42].
We have focused on a heterosexual population. Often,
bisexuality acts as a bridge for transmission between heterosexual
and homosexual subpopulations. This bridging phenomenon is
especially important for the persistence of STIs, such as hepatitis B
virus [43,44]. Because of bisexuality, MSM can be expected to
derive some benefit from a reduced transmission of HPV in the
general population. Our study shows that female-only vaccination
will never achieve the maximum possible reduction in HPV
prevalence among MSM, but the realized reductions could
constitute a considerable health benefit. The extent to which
MSM may benefit from female-only vaccination should be
contrasted with the effectiveness of targeted vaccination of
MSM, who are at high risk for anal cancers [45]. A recent
publication reported that vaccination of MSM remains cost-
effective up to 26 y of age [46], an age range that might render
targeted HPV vaccination acceptable [47]. Targeted vaccination
of homosexual and bisexual men is an important topic for further
investigation.
The free availability of quadrivalent HPV vaccine to young
Australian women has led to a reduced morbidity of genital warts
in STI clinics since 2007, among women as well as heterosexual
men [14]. Vaccinating boys might have brought about a similar—
or even larger—decline in HPV infection rates than has been
observed as a result of female HPV vaccination. Our analysis
suggests this could have been the case if male-to-female
transmissibility is substantially lower than female-to-male trans-
missibility, or if women have a lower degree of natural immunity
than men. The latter is unlikely, because women generally have
higher seroprevalence for HPV vaccine types than men [48]. It has
been shown that persistent infection is associated with a stronger
immune response [49]; hence, the higher seroprevalence in
women likely reflects a higher degree of natural immunity and
possibly an increased duration of the infectious period as
compared to men. There is limited evidence for more efficient
genital HPV transmission from women to men than from men to
women [50], but whether the asymmetry in type-specific
transmission probabilities is large enough to offset the asymmetry
in the duration of the infectious period between men and women is
not clear [51]. Our analysis suggests that female-to-male
transmission would need to be at least twice as likely in a
partnership as male-to-female transmission for male vaccination to
be more effective at reducing overall infection levels than female
vaccination.
Rules for achieving the most effective reduction in the
population prevalence of infection are relevant both for developed
and for developing countries. Given that the worldwide burden of
HPV-related cancer is concentrated in low-resource settings, HPV
vaccines have the potential to dramatically aid global cancer
control [10,52,53]. While prohibitive prices of HPV vaccines are
still a major hurdle to populations in greatest need, increased
access to cheaper vaccines might soon become a reality following
price negotiations and donor support—analogous to hepatitis B
vaccine and antiretroviral treatment initiatives in recent history.
Rational resource allocation is perhaps even more important in
settings with limited resources, especially when the costs of
purchasing vaccine are high in relation to other costs. Moreover,
achieving the largest reduction in population prevalence is
particularly important when a population perspective is employed,
rather than the individual perspective commonly adopted with
regard to HPV vaccination in developed countries. However, the
population-level effectiveness of a single-sex vaccination program
may be hindered by the high occurrence of cofactors (e.g., immune
suppression and HIV infection) that potentially impede immune
responses to vaccination. In populations with a high HIV
prevalence, vaccination of both sexes might be needed to
substantially reduce HPV transmission.
We have focused on HPV, but our findings are also applicable
to other infections. Sex-specific differences in the transmissibility
and in the course of infection are the rule rather than the
exception in the epidemiology of STIs. These differences have
been demonstrated to have implications for the effectiveness of
control strategies directed at either sex, with regard to contact
tracing to prevent secondary transmission [1], screening to prevent
disease and transmission [2], or vaccination to prevent primary
infection [3]. Here, we have argued that prioritization of
prophylactic interventions to the sex with the highest endemic
prevalence should be the norm to achieve an optimal reduction in
the population prevalence of infection. In this regard, prophylactic
interventions need not be restricted to the use of vaccines. Recent
modeling studies have evaluated the epidemiological impact on the
HIV epidemic of male circumcision and the use of vaginal
microbicides [4–6]. These interventions are by definition sex-
specific, but they could benefit both sexes even if preventative
efficacy would be restricted to one sex only [54]. Of note, reducing
the female risk of HIV acquisition was found to have the most
pronounced effect on population incidence because of the higher
HIV prevalence in women as compared to men [55]. It remains to
be determined whether similar rules of thumb apply to different
control modalities.
Our analysis extends previous modeling work on the topic of
male HPV vaccination [17–21]. Our analysis adds a fundamental
understanding of the impact of current vaccination policies, and
the potential benefits of expanding vaccine coverage, by
examining vaccine allocation between males and females from a
general viewpoint. We used a multi-modeling approach to stress
that our findings do not depend on specific modeling assumptions.
The generic predictions from a standard model of heterosexual
transmission are confirmed by a more elaborate HPV transmission
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model, which has been developed to predict the long-term impact
of HPV vaccination in the Netherlands [26,27]. In addition, the
generic predictions for heterosexual transmission are shown to be
robust when the model includes a small proportion of MSM in the
general population. The results from these different models, when
taken together, provide a coherent argument in favor of increasing
female vaccine coverage as far as possible, given the limits set by
vaccine acceptance and economic constraints. Future research
should delineate the extent to which vaccine uptake among girls
can be encouraged, and how much benefit will be derived for
homosexual and bisexual men from a reduced transmission of
HPV in the general population.
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Editors’ Summary
Background. About 10% of cancers in women occur in the
cervix, the structure that connects the womb to the vagina.
Every year, more than a quarter of a million women (85% of
them in developing countries) die because of cervical cancer,
which only occurs after the cervix has been infected with a
human papillomavirus (HPV) through sexual intercourse
(HPV is one of more than thirty sexually transmissable
organisms that, globally, cause many millions of sexually
transmitted infections every year). There are many types of
HPV, a virus that infects the skin and the mucosa (the moist
membranes that line various parts of the body, including the
cervix). Most people become infected with HPV at some time
during their life, but most never know they have been
infected. Some HPV types cause harmless warts on the skin
or around the genital area, and several—in particular HPV16
and HPV18, so-called high-risk HPVs—can cause cervical
cancer (and some other cancers, including anal, penile, head,
and neck cancers). HPV infections are usually cleared by the
immune system, but about 10% of women infected with a
high-risk HPV develop a long-term infection that puts them
at risk of developing cervical cancer.
Why Was This Study Done? Screening programs have
greatly reduced cervical cancer deaths in developed
countries by detecting the cancer early, when it can be
treated. However, it would be better to prevent cervical
cancer ever developing. Moreover, most women in
developing countries do not have access to screening.
Because infection with specific HPV types can cause the
development of some types of cervical cancer, vaccination of
girls against HPV before the onset of sexual activity might be
one way to prevent cervical cancer. Scientists recently
developed a vaccine that prevents infection with HPV16
and HPV18, and HPV vaccination programs have been
introduced in several countries. These programs are
currently directed only at girls because HPV-related illness
and death are higher among women than men, but should
boys also be included in HPV vaccination programs? Men
would benefit directly from immunization against HPV-
related diseases, but, in addition, vaccination of boys might
help to reduce the circulation of HPV in the population,
thereby indirectly improving the protection of women
through so-called ‘‘herd immunity.’’ In this study, the
researchers used mathematical models to investigate
whether vaccinating girls only, boys only, or both sexes is
the most effective way to reduce the population prevalence
of HPV infection (the proportion of the population infected
with HPV).
What Did the Researchers Do and Find? The researchers
first used a range of standard two-sex mathematical models
of infection and transmission in heterosexual populations to
identify general criteria for allocating an HPV vaccine
between the sexes. They found that the most effective
reduction in the population prevalence of HPV infection was
always achieved by single-sex vaccination and that, in most
situations, the preferred strategy was to vaccinate the sex
with the highest prevaccine prevalence of HPV infection. The
researchers confirmed these predictions using a more
elaborate HPV transmission model that incorporated
differences among individuals in age and level of sexual
activity. Importantly, this second analysis also suggested that
for existing girl-only vaccination programs, increasing
coverage of vaccination among girls would bolster herd
immunity more effectively than switching to a policy of
vaccinating both sexes.
What Do These Findings Mean? The findings of this
study suggest that increasing vaccine uptake among
preadolescent girls is a more effective way to reduce HPV
infection than including boys in existing vaccination
programs. They also suggest that directing HPV vaccination
at the sex with the highest prevaccine prevalence of
infection will reduce the population prevalence of HPV
most effectively. Although the accuracy of these findings is
dependent on the assumptions included in the
mathematical transmission models used by the researchers,
these findings support a policy of increasing female HPV
vaccine coverage as far as possible, within the limits set by
vaccine acceptance and economic constraints. More
generally, these findings suggest that single-sex
preventative interventions might be the best way to
reduce heterosexual transmission of other sexually
transmitted infections and that targeting the sex with the
highest prevalence of infection might achieve the most
effective reduction in the population prevalence of these
common diseases.
Additional Information. Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001147.
N The US National Cancer Institute provides information
about cervical cancer for patients and for health profes-
sionals, including information on HPV vaccines (in English
and Spanish)
N The US Centers for Disease Control and Prevention also has
information about cervical cancer and HPV
N The UK National Health Service Choices website has pages
on cervical cancer and HPV vaccination (available in several
languages and including a short video of girls talking
about HPV vaccination)
N The PREHDICT project investigates health-economic mod-
eling of prevention strategies for HPV-related diseases in
European countries; information about this project is
available from the European Cervical Cancer Association
N More information about cervical cancer and HPV vaccina-
tion is available from Macmillan Cancer Support
N Personal stories about cervical cancer are available through
the charity Healthtalkonline
N MedlinePlus provides links to additional resources about
cervical cancer and other sexually transmitted infections (in
English and Spanish)
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